Pseudomonas bacteriophage and uses thereof
AssigneeBiomx Ltd.
InventorsLior Moshe Zelcbuch, Rotem Edgar, Irit Sherman, Dana Inbar, Noa Ben-Yishai, Maya Kahan-Hanum
Life of this patent
Estimating the term…
Abstract
A composition comprising at least two different strains of isolated bacteriophages, each capable of infecting a bacteria of the species Pseudomonas aeruginosa, wherein at least one of said at least two different strains of isolated bacteriophages has a genomic nucleic acid sequence at least 90% identical to one of the nucleic acid sequence as set forth in SEQ ID NOs: 1-10. Uses thereof are also disclosed.
Claims30
A composition comprising at least two different strains of isolated bacteriophages, each capable of (lytically) infecting a bacteria of the species Pseudomonas aeruginosa (e.g., Pseudomonas aeruginosa present in a Cystic Fibrosis patient), wherein at least one of said at least two different strains of isolated bacteriophages has (i) a genomic nucleic acid sequence at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9% or 100%) identical (e.g., in the combined coding region) to one of the nucleic acid sequence as set forth in SEQ ID NOs:
- 1-10, and/or (ii) at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9% or 100%) identical genes (e.g., in the combined region) to the essential genes of a bacteriophage selected from the bacteriophages listed in Table 2, as set forth in Example 7;
- and
- wherein optionally, said at least two different strains of isolated bacteriophages have synergistic redundancy effect, based on either (i) time-to-mutant (TTM) that is at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, or 80% above the longest individual phage TTM with respect to said bacteria, or (ii) normalized area under the curve for OD600-time plot (AUC) that is at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% smaller than the smallest individual phage normalized area under the curve with respect to said bacteria (or a mixture of more than one of said bacteria).
A recombinant bacteriophage capable of infecting bacteria of the species Pseudomonas aeruginosa, wherein said bacteriophage has a genomic nucleic acid sequence at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9% or 100%) identical (e.g., in the combined coding region) to one of the nucleic acid sequences as set forth in SEQ ID NOs:
- 1-10, and wherein said bacteriophage is genetically modified such that the genome thereof comprises a heterologous sequence.
An isolated bacteriophage capable of (lytically) infecting bacteria of the species Pseudomonas aeruginosa (e.g., Pseudomonas aeruginosa present in a Cystic Fibrosis patient), wherein said bacteriophage has a genomic nucleic acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9% or 100%) identical (e.g., in the combined coding region) to one of the nucleic acid sequences as set forth in SEQ ID NOs:
- 1-10.
A method of treating a disease associated with a Pseudomonas aeruginosa infection in a subject in need thereof (e.g., a subject having Cystic Fibrosis), comprising administering to the subject a therapeutically effective amount of a composition comprising at least one isolated bacteriophage strain capable of infecting bacteria of the species Pseudomonas aeruginosa causing the infection, wherein said at least one bacteriophage strain has a genomic nucleic acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9% or 100%) identical (e.g., in the combined coding region) to one of the nucleic acid sequences set forth in SEQ ID NOs:
- 1-10, thereby treating the disease associated with a Pseudomonas aeruginosa infection.
Dependencies are inferred from the claim text.